

## CURRICULUM VITAE

### **Douglas S. Scherr**

e-mail: dss2001@med.cornell.edu

Starr 900, Department of Urology  
The New York Presbyterian Hospital-  
Weill Medical College of Cornell University  
525 East 68th Street  
New York, NY 10021  
Phone: (212) 746-5788  
Fax: (212) 746-0975

### **Education:**

B.A.	Cornell University, Arts & Sciences Ithaca, New York	Government	1989
M.D.	The George Washington University Medical School Washington, D.C.		1994

### **Professional Experience:**

1994-5	Intern, General Surgery The George Washington University Hospital	
1995-6	Junior Assistant Resident, General Surgery The George Washington University Hospital	
1996-9	Resident in Urology The James Buchanan Brady Department of Urology The New York Hospital-Cornell Medical Center New York, N.Y.	
1999-00	Chief Resident in Urology The James Buchanan Brady Department of Urology The New York Hospital-Cornell Medical Center New York, N.Y.	
2000-02	Fellow, Urologic Oncology Department of Urology Memorial Sloan Kettering Cancer Center New York, New York	
7/01-6/02	Instructor in Urology Department of Urology Weill Medical College of Cornell University New York, N.Y.	
7/02-Present	Assistant Professor of Urology Clinical Director, Urologic Oncology Department of Urology	

Weill Medical College of Cornell University  
New York, N.Y.

1/03-present                      Visiting Associate Physician  
Rockefeller University Hospital  
Rockefeller University  
New York, N.Y.

**Professional Organizations:**

Diplomate, American Board of Urology  
Member, Society of Urologic Oncology  
    [Founding Member, Executive Committee, Young Urologic Oncology Society]  
Member, Society for Basic Urological Research  
Member, American Urological Association  
Member, New York Section of AUA, Co-Chair of Valentine Essay Meeting  
Member, Society of University Urologists  
Member, American Medical Association  
Lecturer, American Austrian Foundation  
Member, Cancer and Leukemia Group B (CALGB), GU Core

**Board Certification:**

American Board of Urology (February, 2003)

**Professional Honors/Awards:**

William Beaumont Medical Research Honor Society  
**First Prize** for Best Original Medical Essay, The William Shafirt Award, The George Washington University School of Medicine. "A crisis of unknown proportion: An empirical analysis of the American medical malpractice system." 1994  
**First Prize** for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, "BCL-2 and P53 expression in clinically localized prostate cancer as predictive markers for the response to external beam radiotherapy." 1998  
**First Prize** for Clinical Investigation, Society of University Urology Residents, Annual Chief Resident Meeting, Marietta, Georgia. "Anti-androgen therapy for prostate cancer and the prevention of osteoporosis: The role of DES." 2000  
**Second Prize** for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, "Collagen Type I Crosslinked N-Telopeptide as a urinary marker for osteoporosis in prostate cancer: The role of Diethylstilbestrol (DES)." 2000  
  
**Pfizer, Scholars in Urology Award**, Awarded for advancing the scientific and clinical field of urology. 2000  
**Ferdinand C. Valentine Fellowship for Research in Urology**. The New York Academy of Medicine. 2001-2002. Syndecan-1 expression in prostate cancer and the role of p27 in primary prostate epithelial cell transformation.

**T32 Research Training Grant**. Memorial Sloan Kettering Cancer Center. 2000-2002.

**Edwin Beer Research Award.** NY Academy of Medicine. Effective Tumor Immunotherapy in Transitional Cell Carcinoma of the Bladder. 2005-2007

**Career Development Award.** Kidney Urology Foundation of America. The role of the Pim-1 Oncoprotein in Prostate Carcinogenesis. 2004-2005

**Best Video Award.** Society of Laparoscopic Surgery. Oncological Outcomes of Robotic Cystectomy. San Francisco, CA August, 2007.

**Licensure:**

New York State, 1996 (#204529)

**Research Grants:**

**Current Support and Active Research Work:**

NY Academy of Medicine/Valentine Research Award in Urology  
Role of p27 in Prostate Epithelial Cell Differentiation  
PI: Douglas S. Scherr, M.D.  
Total award: \$50,000

Kidney Urology Foundation of America  
Career Development Award  
The Role of PIM-1 Oncogene in Prostate Carcinogenesis  
PI: Douglas S. Scherr, M.D.  
Total Award: \$50,000

Edwin Beer Research Award  
Effective Tumor Immunotherapy in Superficial Bladder Cancer  
Total Award: \$40,000/year for 2 years

3M Pharmaceuticals  
Phase I Trial of Imiquimod-like Compound in the Treatment of Superficial Bladder Cancer  
PI: Douglas S. Scherr, M.D.  
Total Award: \$112,000

Empire Clinical Research Investigator Award.(ECRIP). Development of Direct Medical Applications of Multiphoton Microscopy to Solve Crucial Diagnostic Challenges in Urology: The Use of Two-Photon Tissue Imaging in the Evaluation and Diagnosis of Malignancy. \$60,000/yr for 2 years

NBIB/NIH Bioengineering Partnership Grant. Multiphoton Endoscopy Development. Co-investigator. \$2,000,000 Award.  
Weill Medical College-Cornell University Seed Grant. PI. The development of multiphoton endoscopy in bladder cancer. \$50,000.

Weill Medical College-Cornell University Seed Grant. PI. Microfluidic Chip Development in the diagnosis of Urothelial Cell Carcinoma. \$50,000.

Pending:

NIH/NCI  
K23 Mentored Research Career Development Award  
Assignment Number: 1 K23 DK068111-01  
BCG and Bladder Tumor Antigen Cross Presentation  
PI: Douglas S. Scherr, M.D.  
Total direct costs: \$315,000  
Priority Score: 180

DOD Idea Development Award. Co-PI  
In Vivo Imaging Development Using Multiphoton Microscopy for Urologic Malignancy

**Active Protocols/Clinical Trials:**

**Effective Tumor Immunotherapy in Bladder Cancer.** *Principal Investigator*, Weill Medical College of Cornell University IRB # 0103-647, Approved 12/02, Renewed Approval 11/03. This protocol employs leukophoresis pre and post-BCG therapy in patients with superficial bladder cancer in an attempt to identify a specific CD-8 lymphocyte response to tumor antigen that is initiated by BCG. A total of 9 patients have enrolled and completed the trial.

**A Randomized, Placebo Controlled Phase II Study of Celecoxib in Patients with Recurrent Superficial Bladder Cancer,** *Co-PI at Cornell Site*, Main PI: Dr. Guido Dalbagni, Memorial Sloan Kettering Cancer Center. Goal is to assess the role of Celecoxib in the prevention of superficial bladder cancer. Weill Medical College of Cornell University IRB # 0903-894.

**Role of Renal Biopsy in the Preoperative Determination of Histology in Patients with Renal Cell Carcinoma.** *Principal Investigator*, Weill Medical College of Cornell University. Intraoperative renal biopsies performed prior to radical or partial nephrectomy with subsequent FISH analysis for pathological interpretation. IRB #: 0802-408.

**Publications:**

1. Schultz PK, Herr HW, Zhang ZF, Bajorin DF, Seidman A, Sarkis A, Fair WR, **Scherr DS**, Bosl GJ, Scher HI. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with five year follow-up. *J Clin Oncol* 12:1394-1401, 1994
2. **Scherr DS**, Poppas DP. Laser tissue welding. In, *Technologic Advances in Urology: Implications for the Twenty-first Century.* *Urol Clin N Amer* 25: 123-35, 1998.
3. Poppas DP, **Scherr, DS.** Laser tissue welding: a urological surgeon's perspective. *Haemophilia* 4:456-462, 1998.
4. **Scherr, DS**, Poppas DP. Laser welding in urology. *AUA Update Series XVII:* pp1-6, 1998.

5. **Scherr, DS**, Chen A, Eid JF. A case report: In vivo excision of an angiomyolipoma from a living related renal transplant. *J Urol*, 163: 1859, 2000.
6. **Scherr, DS**, Vaughan ED Jr, Wei JT, Chung M, Felson D, Allbright R, Knudsen BS: Bc1-2 and P53 Expression in clinically localized prostate cancer predicts the response of patients to external beam radiotherapy. *J Urol* 162: 12-16, 1999.
7. **Scherr, DS**, Goldstein M. Comparison of bilateral versus unilateral varicocelectomy in men with palpable bilateral varicoceles. *J Urol* 162: 85-88, 1999.
8. **Scherr, DS**, Eastham, J, Ohori M, Scardino PT. Prostate biopsy techniques and indications: when, where and how? *Semin Urol Oncol* 20(1):18-31, 2002.
9. **Scherr, DS**, Pitts WR, Vaughan ED. DES Revisited: Anti-androgen therapy, osteoporosis and prostate cancer. *J Urol*, 167: 535-538, 2002.
10. **Scherr DS**, Swindle and Scardino, PT. NCCN Guidelines for the Management of Prostate Cancer. *Urology* 61 (Suppl 2A): 14-24, 2003.
11. **Scherr, DS** and Pitts, WR. Androgen Deprivation Therapy Without Estrogen Deprivation: The Non-Steroidal Effects of Estrogens in the Treatment of Prostate Cancer. *J Urol* 170(5): 1703-08, 2003
12. Knudsen, BS, Gmyrek, GA, Inra, J, **Scherr, DS**, Vaughan, ED, Nanus, DM, Kattan, MW, Gerald, WL and Vande Woude, G. High Expression of the Met receptor in prostate cancer metastasis to bone. *Urology*, 60(60): 1113-1117, 2002.
13. **Scherr, DS**, NG C, Munver, R, Sosa, RE, Vaughan, ED, et al. Practice Patterns Among Urologic Surgeons Treating Localized Renal Cell Carcinoma in the Laparoscopic Age: Technology vs. Oncology. *Urology*, 62(6): 1007-12, 2003.
14. Richstone L, **Scherr, DS**, Reuter, VE, Snyder ME, Rabbani F, Kattan M and Russo P. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. *J Urol*, 171(2 pt 1): 615-20, 2004
15. Chen, DY, Sosa, RE and **Scherr, DS**. Treatment of Adrenocortical Carcinoma: Contemporary Outcomes. *Current Urology Reports*, 5(1): 65-72, 2004
16. Boorjian S, Tickoo S, Mongan N, Nanus D, Yu H, Bok D, Rando R, **Scherr DS**, and Gudas L. Loss of Lecithin:Retinol Acyltransferase (LRAT) Expression Correlates with Increased Pathologic Tumor Stage in Bladder Cancer. *Cancer Res*, 10: 3429-3437, May 15, 2004.
17. Boorjian S, Ugras S, Mongan N, Gudas L, Tickoo S and **Scherr DS**. Androgen Receptor Expression is Inversely Correlated with Pathologic Tumor Stage in

Transitional Cell Carcinoma of the Bladder. Accepted for Publication, *Urology* 64(2): 383-88, 2004.

18. Boorjian S, Ng C, Sosa RE, Munver R, Delpizzo J, Vaughan ED and **Scherr DS**. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. *Urology*, 66(2): 283-7, Aug 2005.
19. Boorjian S, Ng C, Munver R, Palese MA, Sosa RE, Vaughan EDV, Delpizzo JJ and **Scherr DS**. Abnormal Selective cytology results predict recurrence of upper-tract transitional cell carcinoma treated with ureteroscopic laser ablation. *J Endourol*, 18(9): 912-6, Nov 2004.
20. Boorjian, S., **Scherr, D.S.**, Mongan, N.P., Zhuang, Y., Nanus, D.M., and Gudas, L.J. Retinoid Receptor mRNA Expression Profiles in Human Bladder Cancer Specimens. *Int J Oncol*, 26(4): 1041-48, Apr. 2005.
21. Barocas DA, Kawamoto H, Dreizin DF, Howard ME, Choi J, Pitts WR, You X, Tickoo SK, Boorjian SA, **Scherr DS**: Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome. *Urology* 66(5): 1134-39, 2005.
22. Shelton JB, Barocas DA, Conway F, Hart K, Nelson K, Richstone L, Gonzalez RR, Raman JD and **Scherr DS**. Prostate-specific antigen screening in a high-risk population: lessons from the community and how they relate to large scale population based studies. *Urology*, 65(5): 931-6, 2005.
23. Raman, JD, Mongan, NP, Tickoo, SK, Boorjian, SA, **Scherr, DS** and Gudas, LJ. Increased expression of the p16 gene, *EZH2*, in transitional cell carcinoma of the bladder. *Clin Can Res*, 11(24): 8570-76, Dec. 2005.
24. Tu JJ, Akhtar M, Hyjek E, **Scherr DS** and Chen YT. Differential diagnosis of renal cell tumors: An immunohistochemical study using a panel of antibodies. *Am J Surg Pathol*, Accepted for Publication.
25. Raman JD, Ng CK, Boorjian SA, Vaughan EDV, Sosa RE and **Scherr DS**. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. *BJU Int*, 96(7): 1031-5, Nov. 2005.
26. Barocas, DA, Rabbani, F, **Scherr, DS** and Vaughan, EDV. A population based study of renal cell carcinoma and prostate cancer in the same patients. *BJU Int.*, 97(1): 33-6, 2006
27. Raman JD, Palese MA, Ng CK, Boorjian SA, **Scherr DS**, Delpizzo JJ and Sosa RE. Hand-assisted laparoscopic nephroureterectomy for upper urinary tract transitional

- cell carcinoma. *JSLs*, 10(4): 432-8, 2006.
28. Barocas, DA, Rohan, SM, Kao, J, Gurevich, RD, DelPizzo, JJ, Vaughan, ED, Akhtar, M, Chen, YT and **Scherr, DS**. Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis. *J Urol*, 176(5): 1957-62, 2006.
  29. Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, **Scherr DS** and Gudas LJ. Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma. *Carcinogenesis*, 27(3): 499-507, 2006.
  30. Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu, H and **Scherr DS**. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. *J Urol*. 177(6): 2347-51, 2007.
  31. Raman JD, Sosa RE, Vaughan ED and **Scherr DS**. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma. *Urology*, 69(2): 251-4, 2007
  32. Raman JD, Dong S, Levinson A, Samadi D and **Scherr DS**. Robotic radical prostatectomy: operative technique, outcomes and learning curve. *JSLs*, 11(1): 1-7, 2007.
  33. Barocas DA, Mathew S, Delpizzo JJ, Vaughan ED, Sosa RE, Fine RG, Akhtar M and **Scherr DS**. Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hybridization on a needle biopsy specimen. *BJU Int*, 99(2): 290-95, 2007.
  34. Raman JD and **Scherr DS**. Management of patients with upper urinary tract transitional cell carcinoma. *Nat Clin Pract Urol*, 4(8): 432-43, 2007
  35. Wang GJ, Barocas DA, Raman JD and **Scherr DS**. Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. *BJU Int*. Sept. 2007.
  36. Liu H, Schwartz MJ, Hwang D and **Scherr DS**. Tumor Growth inhibition by an imidazoquinoline is associated with c-myc down regulation in urothelial cell carcinoma. *BJU Int*. In press, 2007.
  37. Schwartz MJ, Hwang D, Hung A, Han J, Vaughan ED and **Scherr DS**. The negative influence of changing biopsy practice patterns on the predictive value of prostate specific antigen for cancer detection on prostate biopsy. *Cancer*, 2007. In Press.
  38. Richstone L, Bianco FJ, Shah H, Kattan MW, Eastham JA, Scardino PT and **Scherr DS**. Radical prostatectomy in men seventy years or older: impact of age on upgrading, upstaging and preoperative nomogram accuracy. *BJU Int*. 2007. In Press.
  39. Seandel M, James D, Shmelkov SV, Falciatori I, Kim J, Chavala S, **Scherr DS**, Zhang F, Rorres R, Gale NW, Yancopoulos GD, Murphy A, Valenzuela DM, Hobbs

RM, Pandolfi PP and Rafii S. Generation of functional multipotent adult stem cells from GPR 125+ germline progenitors. *Nature*. 449(7160): 346-50, Sept. 2007.

**Book Chapters:**

1. **Scherr, DS**, Manyak MJ. Bladder Tumors and Calculi. In Sosa RE, Albala DM, Jenkins AD, Perlmutter, AP, eds. *Textbook of Endourology*. Philadelphia: WB Saunders and Co; 1997
2. **Scherr, DS**, Bosworth J, Steckel J. Complications of brachytherapy in the treatment of localized prostate cancer. In: Smith, Teneja, et al, eds. *Complications of Urologic Surgery*. 3<sup>rd</sup> ed. 2000.
3. **Scherr DS** and Barocas DA. Hinman's Atlas of Urologic Surgery. Principles of non-continent urinary diversion. Editor, Joseph A. Smith. In Press. 2007.

**Abstracts:**

1. **Scherr, DS**, Simmons R, Russo P. Multifocal renal cell carcinoma: a descriptive analysis [Abstract]. Presented at American Urological Association, Anaheim, CA 2001.
2. **Scherr, DS**, Pavlovich CP, Pitts, WR, Vaughan, ED. Collagen type I Crosslinked N-telopeptide as a urinary marker for osteoporosis in prostate cancer [Abstract]. Presented at American Urological Association, Atlanta, GA. 2000.
3. **Scherr, DS**, Vaughan ED, Wei JT, Chung M, Felsen D, Albright R, Knudsen B. Bcl-2 and P53 expression in clinically localized prostate cancer can predict the response to external beam radiotherapy. [Abstract] Presented at American Urological Association, Dallas, TX. 1999.
4. **Scherr, DS**, Choi B, Su LM, Moomjy M, Schlegel PN, Goldstein M. Pregnancy after testicular sperm extraction at the time of radical orchiectomy for cancer in a solitary testis. [Abstract] Presented at American Urological Association, San Diego, CA, 1998.
5. **Scherr, DS**, Goldstein M: Comparison of bilateral vs unilateral varicocelectomy in men with palpable bilateral varicoceles [Abstract]. Presented at American Urological Association, San Diego, CA. 1998.
6. Boorjian S, Ng C, Palese M, Sosa RE, Delpizzo J, Vaughan ED and **Scherr DS**. Delay in time to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma does not impact postoperative disease status. Presented at 2004 AUA, San Francisco, CA.
7. Boorjian S, Ng C, Munver R, Sosa RE, Vaughan ED and **Scherr DS**. Abnormal urinary cytology predicts increased tumor recurrence in upper tract transitional cell carcinoma treated with endoscopic laser ablation. Presented at 2004 AUA, San Francisco, CA.
8. Smith E, Albert M, Albert P, You X, Masse D and **Scherr DS**. Antigen cross presentation and cross priming in the treatment of superficial bladder cancer: The role of BCG-invoked specific CD8+ T lymphocyte response against bladder tumor antigen. Presented at 2004 AUA, San Francisco, CA.
9. Richstone L, Shah H, Chen H, Kattan M, Schlegel PN, Vaughan ED, Eastham J, Scardino PT and **Scherr DS**. Radical prostatectomy (RRP) in men >70 years old: Effect of age on

upgrading, upstaging and accuracy of preoperative nomograms. Presented at 2004 AUA, San Francisco, CA.

10. Boorjian S, Ng C, Munver R, Sosa RE, Vaughan ED and Scherr DS. Stage migration of upper tract transitional cell carcinoma: An argument for the continued role of endourologic diagnosis and treatment. Presented at 2004 AUA, San Francisco, CA.

**Visiting Fellow/Professorships:**

- 2/98 Visiting fellowship, February, 1998; Salzburg General Hospital, Salzburg, Austria
- 12/02 Visiting Professorship, December 6-13, 2002, Salzburg Seminar, Salzburg, Austria
- 8/07 Visiting Professorship. Salzburg Seminars. Surgical Management of bladder Cancer.

**Invited Lectures:**

- 10/02 The Changing Face of Hormonal Therapy in the Treatment of Prostate Cancer, Urology Grand Rounds, Brookdale Hospital, New York
- 9/03 A Modern Approach in the Treatment of Testicular Germ Cell Tumors. General Surgery Grand Rounds, Weill Medical College of Cornell University. Septmeber, 2003
- 11/05 2005 Mini-Board Review for Residents. Management of Superficial Bladder Cancer. NY Academy of Medicine.
- 11/06 Course Director, Current Trends in GU Malignacies. New York Marriot.

**Broadcast Interviews:**

- 9/03 WNBC-TV New York: "Treatment Options for Prostate Cancer"
- 9/03 NY-1-TV New York: "Radiation and Surgical Treatments of Prostate Cancer"
- 2/04 WNBC-TV New York, "Screening for prostate cancer in African American Men"